Article
Friend or foe: can activating mutations in NOTCH1 contribute to a favorable treatment outcome in patients with T-ALL?
Critical reviews in oncogenesis - 1 Jan 2014
Goldshtein Aviya, Berger Michael
Abstract excerpt
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes. Despite significant improvement in the treatment of T-ALL, approximately 20% of children and most adults succumb to resistant or relapsed disease. Transformation events occur during crucial steps of thymocyte development and have been related to the expression of certain oncogenes such as TAL2, TLX1, LYL1, LMO1, and NOTCH1....
Topics
- Humans
- Mutation
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
- Receptor, Notch1
- Treatment Outcome